Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Top Pharma Firms Prosper; Private Innovators Likely To Lead Sector

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's strengthening regulation of the pharmaceutical sector and expanding national health insurance coverage, along with rising incomes, are all triggering a boom for the country's leading drug makers, according to a new study of the sector

You may also be interested in...



Despite Global Crisis, China’s Strongest Pharma Firms Likely To Thrive In 2009 Through Innovation And Acquisitions

BEIJING - Despite the Western world's financial meltdown and China's own faltering economic growth rates, the country's leading pharmaceutical companies are forecast to expand through 2009 by developing innovative drugs and by outlasting or even merging with their weakest competitors

Despite Global Crisis, China’s Strongest Pharma Firms Likely To Thrive In 2009 Through Innovation And Acquisitions

BEIJING - Despite the Western world's financial meltdown and China's own faltering economic growth rates, the country's leading pharmaceutical companies are forecast to expand through 2009 by developing innovative drugs and by outlasting or even merging with their weakest competitors

China Medicine To Enter U.S. Market With Weight Loss Tablets

BEIJING - China Medicine Corp. is preparing to launch its first product in the U.S., a dietary supplement aimed at weight loss and countering obesity, according to the company's CEO

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel